Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
terutroban
- Development stage
- Phase 3
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Terutroban is a small molecule, orally active antiplatelet agent that was developed by Servier. It functions as a selective antagonist of the thromboxane prostanoid (TP) receptor, blocking the actions of thromboxane A2 (TXA2) to inhibit platelet aggregation and provide vasoprotective effects. The drug was primarily evaluated for the secondary prevention of cerebrovascular and cardiovascular events in patients with a history of ischaemic stroke or transient ischaemic attack (TIA). However, the pivotal Phase III PERFORM trial was halted early in 2010 after terutroban failed to show non-inferiority compared to aspirin, leading to the discontinuation of its clinical development.
- Other names
- terutroban
02
Targets
TYMP (Thymidine phosphorylase)
Beyond the preview
Go deeper on terutroban.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on terutroban.